US Patent 6927043 Interleukin-2 mutein expressed from mammalian cells
Patent 6927043 was granted and assigned to Bayer Corporation on August, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 15 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 Oct, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+232 characters)
Article
Patent abstract
Glycosylated interleukin-2 muteins are described. A method of producing the muteins using mammalian cells is included. The muteins may be incorporated into pharmaceutical preparations useful for, e.g., cancer therapy.
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Ruth Kelly0
Sham-Yuen Chan0
Date of Patent
August 9, 2005
0Patent Application Number
100516570
Date Filed
January 22, 2002
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6927043 Interleukin-2 mutein expressed from mammalian cells
Find more entities like US Patent 6927043 Interleukin-2 mutein expressed from mammalian cells
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
